Welcome to our dedicated page for Infusystem Hld SEC filings (Ticker: INFU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
InfuSystem Holdings, Inc. filings document financial reporting, governance and material-event disclosures for a health care service provider focused on outpatient durable medical equipment services. Recent 8-K filings furnish earnings releases, conference-call announcements, investor presentations and Regulation FD disclosures tied to Patient Services and Device Solutions.
The company’s proxy materials cover board matters, shareholder voting, executive compensation and equity award disclosures. Other filings document accounting oversight, including changes in the independent registered public accounting firm, audits of consolidated financial statements and internal control over financial reporting.
Minerva Advisors LLC and related entities report owning 1,078,731 shares of InfuSystem Holdings common stock, representing 5.3% of the company’s outstanding shares. The ownership is reported on a Schedule 13G/A as of 12/31/2025 and is based on 20,336,183 shares outstanding as of October 31, 2025.
The stake is held across Minerva Advisors LLC, Minerva Group, LP, Minerva GP, LP, Minerva GP, Inc., and David P. Cohen, with 764,517 shares held by Minerva Group, LP. The filers certify the securities are not held for the purpose of changing or influencing control, other than activities solely in connection with a nomination under Rule 14a-11.
InfuSystem Holdings, Inc. filed a current report announcing the timing of its upcoming financial disclosure. The company plans to release preliminary fourth quarter and full-year 2025 results on February 24, 2026 before the market opens.
InfuSystem will host an investor conference call on the same day at 9:00 a.m. Eastern Time to discuss these results, with both live webcast access and a telephone replay available through early March. The filing clarifies that the related press release is furnished under Regulation FD and is not deemed filed for liability purposes.
InfuSystem Holdings, Inc. reported that the Centers for Medicare and Medicaid Services (CMS) has added two of the electronic infusion pumps it uses in its Pain Management services business to the list of qualifying products for separate payment under the Non-Opiods Prevent Addiction in the Nation (NOPAIN) Act. This means those specific non-opioid pain management pumps can be reimbursed separately by CMS, rather than being bundled into broader procedure payments.
The update highlights growing recognition of non-opioid pain management options within federal reimbursement programs, which may help support adoption of InfuSystem’s CMS-qualifying pumps within its Pain Management services line.
InfuSystem Holdings, Inc. furnished an Investor Presentation dated November 13, 2025 under Item 7.01 (Regulation FD). The presentation is attached as Exhibit 99.1.
The materials are expressly furnished, not filed, and therefore are not subject to Section 18 liabilities and are not incorporated by reference into other Securities Act or Exchange Act filings.
InfuSystem Holdings (INFU): AWM Investment Company filed Amendment No. 11 to Schedule 13G reporting beneficial ownership of 561,656 shares of InfuSystem common stock, representing 2.8% of the class.
AWM reports sole voting and sole dispositive power over these shares. The filing states AWM acts as investment adviser to Special Situations Life Sciences Fund, L.P., which holds the shares. The certification indicates the securities were acquired and are held in the ordinary course of business and not to change or influence control. Item 5 confirms ownership of 5 percent or less of the class. The date of the event requiring the filing is 09/30/2025.
InfuSystem Holdings, Inc. announced that President and CEO Carrie Lachance and CFO Barry Steele will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025.
The company furnished this update under Item 7.01 (Regulation FD). A related press release was provided as Exhibit 99.1 and is designated as furnished, not filed, under the Exchange Act.
InfuSystem Holdings (INFU) reported higher Q3 results. Net revenues were $36,488k, up from $35,320k. Gross profit rose to $20,820k and operating income reached $3,811k. Net income was $2,259k, or $0.11 per diluted share, compared with $1,807k, or $0.08 per share, a year ago.
For the first nine months, net revenues were $107,206k versus $101,013k, with net income of $4,591k ($0.22 diluted). Cash provided by operating activities was $17,282k, reflecting stronger cash generation. The company repurchased $8,563k of common stock year-to-date under its $20,000k authorization.
Segment mix in Q3 showed Patient Services external revenue of $22,363k and Device Solutions external revenue of $14,125k. InfuSystem acquired certain assets of Apollo Medical Supply for $1,412k to expand wound care within Patient Services. The revolving credit facility had $21,360k outstanding and $53,640k available, with maturity extended to July 15, 2030.
InfuSystem Holdings (INFU) furnished its third-quarter 2025 results via an 8-K. The company reported that a press release detailing Q3 2025 financial results was provided under Item 2.02 and attached as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act, and therefore not subject to Section 18 liabilities. The filing also includes the Inline XBRL cover page file as Exhibit 104.
InfuSystem Holdings, Inc. announced it will disclose its third‑quarter 2025 financial results on November 4, 2025 before the market opens. The company will host a conference call for investors the same day at 9:00 a.m. Eastern Time.
The related press release is furnished as Exhibit 99.1.
InfuSystem Holdings (INFU) insider transaction: EVP-Chief HR Officer Jerod Funke reported RSU settlement on October 9, 2025. Restricted stock units converted into common stock on a one-for-one basis, resulting in 12,500 shares acquired at $0 per share via code “M”. To cover taxes, the issuer withheld 3,669 shares at $9.61 under code “F”.
After these transactions, Funke directly owned 18,662 shares of InfuSystem common stock.